PKI News and Press, PerkinElmer Inc. From 01/24/23

Danaher ( NYSE: DHR ), which reported slowing topline growth in its Q4 2022 financial results earlier Tuesday, is impacting other life sciences tools and services providers. The biggest decliner among peers is Repligen ( NASDAQ: RGEN ), off ~4.3% . Others include Thermo Fi...

Summary Bruker offers a range of advantages over peers: profitability, value, growth, and more. As such, the company is well-positioned to provide strong returns in the future. This article will address recent developments, highlight the advantages, and discuss the opportunity. ...

PerkinElmer, Inc. (PKI) 41st Annual J.P. Morgan Healthcare Conference Call January 10, 2023 11:15 AM ET Company Participants Prahlad Singh - President and Chief Executive Officer Conference Call Participants Rachel Vatnsdal - JPMorgan Chase & Co. Presenta...

PerkinElmer ( NYSE: PKI ) said that it expects its Q4 2022 results to meet or exceed guidance given in November. Back then, the life sciences company projected pro forma total revenue is  $1.06B-$1.07B vs. consensus of $1.07B and pro forma adjusted earnings per share of $...

PerkinElmer Inc. , (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that it will release its fourth quarter and full year 2022 financial results prior to market open on Tuesday, February 14, 2023. The Company will host a conference call the same day at...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes trading in ...

Streamlined workflows aim to shorten research and development for novel therapies to combat diseases like cancer and Alzheimer's PerkinElmer, Inc. , (NYSE:PKI), a global leader committed to innovating for a healthier world, today launched ready-to-use Adeno-associa...

Summary PerkinElmer, Inc. might have outperformed the S&P 500 over the last decade, but it didn't perform as well as some of its peers. PerkinElmer has many similarities to Danaher Corporation and could be a great buy here. Both companies recently announced divestitures to...

Summary Following its restructuring and capital budgeting initiatives of FY22, we continue to rate PerkinElmer a buy. The stock has pushed off its October lows and there's strong institutional buying volume into the latest rally. Recent developments have also unraveled since Q...

The US FDA has granted approval to PerkinElmer's ( NYSE: PKI ) EONIS SCID-SMA assay kit for in vitro diagnostic (IVD) use for spinal muscular atrophy ( SMA ) and severe combined immunodeficiency ( SCID ) in newborns. The platform uses PCR technology to screen f...